US2022395510A1PendingUtilityA1
Nucleotide Analogs
Est. expirySep 15, 2034(~8.1 yrs left)· nominal 20-yr term from priority
C07F 9/65616C07F 9/657181A61P 15/00C07F 9/6574C07F 9/65744A61K 33/42A61P 35/00A61P 31/20C07F 9/6561C07F 9/65742A61K 31/522A61K 8/24Y02A50/30A61K 31/00C07F 9/40C07F 9/6571A61P 31/12A61K 31/675A61K 9/06A61K 9/02
83
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A pharmaceutical composition comprising a compound selected from
or a pharmaceutically acceptable salt thereof, in a pharmaceutically acceptable carrier.
2 . The pharmaceutical composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
3 . The pharmaceutical composition of claim 2 , wherein the composition is suitable for topical delivery.
4 . The pharmaceutical composition of claim 3 , wherein the composition is a cream or gel.
5 . The pharmaceutical composition of claim 2 , wherein the composition is a suppository.
6 . The pharmaceutical composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
7 . The pharmaceutical composition of claim 6 , wherein the composition is suitable for topical delivery.
8 . The pharmaceutical composition of claim 7 , wherein the composition is a cream or gel.
9 . The pharmaceutical composition of claim 6 , wherein the composition is a suppository.
10 . The pharmaceutical composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
11 . The pharmaceutical composition of claim 10 , wherein the composition is suitable for topical delivery.
12 . The pharmaceutical composition of claim 11 , wherein the composition is a cream or gel.
13 . The pharmaceutical composition of claim 10 , wherein the composition is a suppository.
14 . The pharmaceutical composition of claim 1 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
15 . The pharmaceutical composition of claim 14 , wherein the composition is suitable for topical delivery.
16 . The pharmaceutical composition of claim 15 , wherein the composition is a cream or gel.
17 . The pharmaceutical composition of claim 14 , wherein the composition is a suppository.
18 . A method for the treatment of a disease selected from human papilloma virus, cervical intraepithelial neoplasia, vaginal intraepithelial neoplasia and anal intraepithelial neoplasia comprising administering a compound selected from
or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier.
19 . The method of claim 18 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
20 . The method of claim 19 , wherein the disease is human papilloma virus.
21 . The method of claim 19 , wherein the disease is cervical intraepithelial neoplasia.
22 . The method of claim 18 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
23 . The method of claim 22 , wherein the disease is human papilloma virus.
24 . The method of claim 22 , wherein the disease is cervical intraepithelial neoplasia.
25 . The method of claim 18 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
26 . The method of claim 25 , wherein the disease is human papilloma virus.
27 . The method of claim 25 , wherein the disease is cervical intraepithelial neoplasia.
28 . The method of claim 18 , wherein the compound is
or a pharmaceutically acceptable salt thereof.
29 . The method of claim 28 , wherein the disease is human papilloma virus.
30 . The method of claim 28 , wherein the disease is cervical intraepithelial neoplasia.Join the waitlist — get patent alerts
Track US2022395510A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.